Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2006-01-09
2010-06-29
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C564S097000
Reexamination Certificate
active
07745490
ABSTRACT:
Substituted n-aryl benzamides, related compounds and their pharmaceutically acceptable derivatives, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, including Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment are provided.
REFERENCES:
Chawla et al., “Challenges in Polymorphism of pharmaceuticals”, CRIPS vol. 5, No. 1, Jan.-Mar. 2004, p. 9-12.
Chandra et al, “Design, synthesis, and structure-activity relationship of novel thiophene derivatives for b-amyloid plaque imaging”, Bioorganic&medicinal chemistry letters 16 (2006), 1350-1352.
http://en.wikipedia.org/wiki/Prodrug (**1 Page Double-Sided**).
Han et al., “Targeted prodrug design to optimize drug delivery”, The aaps journal, (p. 1-17) of 17.
http://en.wikipedia.org/wiki/Levodopa (**2 Pages Double-Sided**).
Neve et al, “The cell cycle as a therapeutic target for Alzheimer's disease”, Pharmacology&Therapeutics, 111 (2006), 99-113.
Snow et al., CAPLUS AN 2003:972023 (**3 Pages**).
Walker et al., Biochem. Pharm., 69 (2005), 1001-1008.
CNSS Spectrums, www.cnsspectrums.com/aspx/articledetail.aspx?articleid=972.
Yamashita et al., caplus an 2000:12674.
Soto, “Protein misfolding and disease; protein refolding and therapy”,FEBS Letters: 498 204-207 (2001).
Porat et al., “Inhibition of amyloid fibril formation by polyphenols: structural similarities and aromatic interactions as a common inhibition mechanism”, Chem Biol Drug Des: 67: 27-37 (2006).
Ono et al., Potent anti-amyloidogenic and fibril destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease,Journal of Neurochemistry: 87, 172-181 (2003).
Dauer, W., and Przedborski, S. 2003. Parkinson's Disease: Mechanisms and Models.Neurons, vol. 39:889-909, (2003).
Polymeropoulos et al., Mapping of a gene for Parkinson's disease to chromosome 4q21-q23,Science, 276:1197-1199, (1997).
Papadimitriou et al., Mutated alpha-synuclein gene in two Greek kindreds with familial PD: incomplete penetrance?,Neurology, 52:651-654, (1999).
Lee et al., Mechanisms of Parkinson's Disease Linked to Pathological a-Synuclein: New Targets for Drug Discovery,Neuron52, 33-38, (2006).
James, et al., Aβ peptide immunization reduces. behavioural impairment and plaques in a model of Alzheimer's disease,Nature, 408:979-982 (2000).
Morgan, et al., Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease,Nature, 408:982-985 (2000).
Castillo Gerardo M.
Lake Thomas P.
Nguyen Beth P.
Snow Alan D.
Weigele Manfred
Eagen Rebecca
Loewe Sun Jae Y
Proteotech Inc.
Shameem Golam M. M.
LandOfFree
Substituted N-aryl benzamides and related compounds for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted N-aryl benzamides and related compounds for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted N-aryl benzamides and related compounds for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4242993